US Senate slams Bush Medicare Rx plan

19 January 2001

While US President George Bush's nominee for Secretary of Health andHuman Services, Wisconsin Governor Tommy Thompson, was welcomed at his confirmation hearing by the Senate Finance Committee, both Republican and Democrat members of the Committee criticized the new administration's plans for Medicare, reports Reuters Health.

One Bush proposal, to provide states with funds to help only low-income Medicare recipients with high prescription drug costs, was "ill-advised and ill-conceived" and is opposed by many Members of Congress and state governors, noted Democrat John Breaux.

Gov Thompson replied that he and President Bush would be "ecstatic" if Congress were to agree speedily on broad Medicare reforms which included prescription drug coverage, but they were determined to send this plan to Congress. The new President "wants to make sure that if nothing else passed, low-income people will be able to get prescription drugs," he said.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight